WO1999007827A1 - Use of lactobacillus for reduction of the fibrinogen level in blood - Google Patents

Use of lactobacillus for reduction of the fibrinogen level in blood Download PDF

Info

Publication number
WO1999007827A1
WO1999007827A1 PCT/SE1998/001423 SE9801423W WO9907827A1 WO 1999007827 A1 WO1999007827 A1 WO 1999007827A1 SE 9801423 W SE9801423 W SE 9801423W WO 9907827 A1 WO9907827 A1 WO 9907827A1
Authority
WO
WIPO (PCT)
Prior art keywords
lactobacillus
blood
fibrinogen
strain
level
Prior art date
Application number
PCT/SE1998/001423
Other languages
French (fr)
Inventor
Hanna Bukowska
Marie-Louise Johansson
Marek Naruszewicz
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR10-2000-7001211A priority Critical patent/KR100517755B1/en
Application filed by Probi Ab filed Critical Probi Ab
Priority to CA2297023A priority patent/CA2297023C/en
Priority to AU83726/98A priority patent/AU729413B2/en
Priority to PL98338578A priority patent/PL194697B1/en
Priority to NZ502610A priority patent/NZ502610A/en
Priority to IL13411398A priority patent/IL134113A0/en
Priority to US09/485,190 priority patent/US6214336B1/en
Priority to DE69834560T priority patent/DE69834560T2/en
Priority to JP2000506312A priority patent/JP4651814B2/en
Priority to EP98934131A priority patent/EP0990024B1/en
Priority to BR9811825-0A priority patent/BR9811825A/en
Publication of WO1999007827A1 publication Critical patent/WO1999007827A1/en
Priority to NO20000268A priority patent/NO324881B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/856—Lactobacillus casei
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus
    • Y10S435/857—Lactobacillus plantarum

Definitions

  • the present invention refers to the use of strains of Lactobacillus being able to reduce the fibrinogen level, and optionally also the cholesterol level, in blood.
  • Fibrinogen is a plasma protein, synthesized in the liver, which in the final step of the blood coagulation cascade by activated thrombin is converted into insoluble fibrin.
  • Fibrin in turn, is in the fibrinolysis reaction decomposed by plasmin, also referred to as fibrinolysin, the normal mechanism for the removal of small fibrin clots from the circulation.
  • the plasma fibrinogen concentration increases gradually during normal aging from an average of 2.3 mg/ml at 20 years to 3.5 mg/ml at 70 years of age. The increase is coupled with about a 20 % decrease in endogenous fibrinolytic activity over the same period. Under conditions of stress or trauma the blood fibrinogen level may double or triple within 48 hours. It has been confirmed that blood fibrinogen is a major determinant of blood and plasma viscosity in the microcirculation, of red cell and platelet aggregation and in the growth of atheromatous lesions. Blood fibrinogen levels are increased and the endogenous fibrinolytic activity decreased by conditions or factors which raise plasma free fatty acid, FFA, levels, see Pickart, ., in Pharmacology 23: 271-280, 1981.
  • Serum cholesterol levels generally refer to a combination of HDL, high density lipoproteins, and LDL, low density lipoproteins. Increased levels of LDL cholesterol may be associated with the pathogenesis of atherosclerosis while higher levels of HDL cholesterol appear to lower the risk of heart disease.
  • antilipidemic agents which in addition to a prolonged reduction in plasma FFA levels also reduce blood fibrinogen concentrations while enhancing fibrinolytic activity apparently by decreaseing hepatic synthesis of fibrinogen and antifibrinolysins, see Pickart, L., Pharmacology 23(5), 271-80, 1981.
  • these agents which are biochemically and structurally diverse, can be mentioned allylpropyl disulfide, the active principle from garlic and onion, acetylsalicylic acid and clofibrate, a fatty acid analogue. Most of these agents have annoying or serious side effects and more efficacious agents should be aimed at.
  • the invention consequently refers to the use of a strain of Lactobacillus for the manufacture of a medicament for reduction of the fibrinogen level in blood in mammals including man.
  • the administered strain of Lactobacillus also brings about a decrease in the serum cholesterol level .
  • the invention therefore also refers to the use of a strain of
  • Lactobacillus for the manufacture of a medicament for reduction of the fibrinogen level as well as the cholesterol level in blood.
  • the invention also refers to the use of a strain of Lactobacillus in combination with an antihyperlipoprotein- emically active substance for the manufacture of a medicament for reduction of the fibrinogen level, as well as the cholesterol level, in blood.
  • a strain of Lactobacillus in combination with an antihyperlipoprotein- emically active substance for the manufacture of a medicament for reduction of the fibrinogen level, as well as the cholesterol level, in blood.
  • the invention refers to the use of a strain of Lactobacillus for the manufacture of a medicament for the prophylaxis and/or treatment of circulatory diseases, such as atherosclerosis, cardiovascular diseases, coronary heart disease, myocardial infarction, ischemic heart disease, stroke.
  • a preferred strain o ⁇ Lactobacillus should be able to survive the passage through the stomach to the gastrointestinal tract and be able to colonize in the intestines.
  • Two factors seem to be crucial for the exertion of ecological effects of Lactobacilli . The first is the capacity to colonize the intestine, that is to survive in high numbers for a period of time after the last administration of live bacteria. The second is the capacity to bind directly to intestinal epithelial cells.
  • Said application especially refers to two new Lactobacillus strains, which have been deposited according to the Budapest Agreement at the DSM - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH -, Braunschweig, Germany on July 2, 1991, that is L. plantarum 299, number DSM 6595, and L. casei ssp. rhamnosus 271, number DSM 6594, as well as variants thereof.
  • a preferred strain is Lactobacillus plantarum 299v, which has been deposited at the DSM on March 16, 1995 under number DSM 9843. This strain as well as other strains of L. plantarum are described in the International patent applica-tion WO 96/29083.
  • the Lactobacillus strain can be administered in any food or pharmaceutical composition which can preserve the viability of the strain in the large intestine.
  • the composi- tion according to the invention can be administered in any suitable way, preferably orally or rectally, for example in the form of enema. It can also be administered enterally through a catheter inserted in the intestines via the stomach or directly in the intestines.
  • a carrier for the strain of Lactobacillus in the pharmaceutical composition is for example a physiologically acceptable substrate fermented by the bacterium in question, especially based on starch or milk.
  • a suitable substrate could contain liquid or solid fibres which are not resorbed in the gastro-intestinal tract.
  • starch- containing substrates can be mentioned cereals, such as oats and wheat, corn, root vegetables such as potatoes and certain fruits such as green bananas .
  • a preferred substrate for the pharmaceutical .composition according to the invention which also gives the composition an excellent nutritional value, is a nutrient solution based on oatmeal, for instance as described in WO 89/08405.
  • the fermented product can also be mixed with a foodstuff, preferably based on fruit or berries, such as rose- hip, blueberries, strawberries, but also with inert solid or liquid substances, such as saline or water.
  • the treatment should take place once or several times daily for a continuous period.
  • the strain of Lactobacillus should be administered in a daily dose of not less than about 10 10 bacteria.
  • the ProViva ® food product was a rose-hip drink containing oats (0.75 g of oat flour, that is 0.07 g of oat fibre/100 ml) .
  • the product contains approximately 5 x 10 7 cfu/ml of Lactobacillus plantarum 299 v and about 0.035 g of DL-lactic acid/100 ml.
  • the fermented oats and the rose-hip drink were made separately and then mixed together in the ratio 5 % (vol/vol) of fermented oats (containing 18.5 % (vol/vol) of oat flour) and 95 % (vol/vol) of rose-hip drink.
  • Plain rose-hip drink consisting of rose-hip powder, sucrose, thickening agent, citric acid, ascorbic acid and water, was used as placebo.
  • the two products were both manufactured by Skanemejerier (Lunnarp, Sweden) .
  • Cholesterol and triglyceride levels in serum were determined using enzyme kits (CHOD-PAP, GPO-PAP) .
  • HDL- cholesterol was measured after precipitation of lipoproteins containing apoB with phosphotungstic acid in the presence of
  • LDL-cholesterol was determined after precipitation of LDL with polyvinyl sulfate. Laboratory procedures were based on test kits from Boehringer-Mannheim. Glucose was measured using glucose oxidase and test kits from Analco (PAP) and plasma fibrinogen determinations followed the method of Clauss based on thrombin time (test kits from bioMerieux) .
  • fibrinogen is an independent risk factor of ischemic heart disease and its level in blood is regulated by genetic and environmental factors.
  • ProViva decreases both the level of fibrinogen and cholesterol may make it a promising food product in the early prevention of ischemic heart disease.

Abstract

The invention refers to the use of a strain of Lactobacillus for the manufacture of a medicament for reduction of the fibrinogen level, and optionally cholesterol level, in blood. Said medicament can be utilized for the prophylaxis and/or treatment of circulatory diseases.

Description

USE OF LACTOBACILLUS FOR REDUCTION OF THE FIBRINOGEN LEVEL IN BLOOD
The present invention refers to the use of strains of Lactobacillus being able to reduce the fibrinogen level, and optionally also the cholesterol level, in blood.
Background of the invention
Fibrinogen is a plasma protein, synthesized in the liver, which in the final step of the blood coagulation cascade by activated thrombin is converted into insoluble fibrin.
Fibrin in turn, is in the fibrinolysis reaction decomposed by plasmin, also referred to as fibrinolysin, the normal mechanism for the removal of small fibrin clots from the circulation. The plasma fibrinogen concentration increases gradually during normal aging from an average of 2.3 mg/ml at 20 years to 3.5 mg/ml at 70 years of age. The increase is coupled with about a 20 % decrease in endogenous fibrinolytic activity over the same period. Under conditions of stress or trauma the blood fibrinogen level may double or triple within 48 hours. It has been confirmed that blood fibrinogen is a major determinant of blood and plasma viscosity in the microcirculation, of red cell and platelet aggregation and in the growth of atheromatous lesions. Blood fibrinogen levels are increased and the endogenous fibrinolytic activity decreased by conditions or factors which raise plasma free fatty acid, FFA, levels, see Pickart, ., in Pharmacology 23: 271-280, 1981.
An increased level of fibrinogen is associated with an increased erythrocyte sedimentation rate, which in turn since long has been correlated to a risk for ischemic heart diseases . In acute myocardial infarction the level of plasma fibrinogen as well as the level of free fatty acids are increased. Fibrinogen as a cardiovascular risk factor is described by Ernst, E., et al . , Annals of Internal Medicine 118: 956-963, 1993. In six prospective epidemiologic studies the correlation of fibrinogen levels on the subsequent incidence of myocardial infarction, stroke and peripheral arterial occlusive disease was assessed and the causality of the association was analysed. All prospective studies showed that fibrinogen was associated with subsequent myocardial infarction or stroke. It was concluded that fibrinogen is pathophysiologically related to cardiovascular events and can be considered a major cardiovascular risk factor.
There are several determinants of the fibrinogen level in health and disease, some of which can not be affected such as age, sex and heritage. Others which are amenable to change are lifestyle determinants such as smoking, sedentary life, diet and stress.
An increased cholesterol level, as well as an increased blood pressure are other important risk factors for heart diseases. Serum cholesterol levels generally refer to a combination of HDL, high density lipoproteins, and LDL, low density lipoproteins. Increased levels of LDL cholesterol may be associated with the pathogenesis of atherosclerosis while higher levels of HDL cholesterol appear to lower the risk of heart disease.
Prior art
There are a wide variety of antilipidemic agents which in addition to a prolonged reduction in plasma FFA levels also reduce blood fibrinogen concentrations while enhancing fibrinolytic activity apparently by decreaseing hepatic synthesis of fibrinogen and antifibrinolysins, see Pickart, L., Pharmacology 23(5), 271-80, 1981. As examples of these agents, which are biochemically and structurally diverse, can be mentioned allylpropyl disulfide, the active principle from garlic and onion, acetylsalicylic acid and clofibrate, a fatty acid analogue. Most of these agents have annoying or serious side effects and more efficacious agents should be aimed at. There are conflicting data regarding the potential hypo-cholesterolemic effect of fermented dairy products in man, and whether intake of these" products has any significance in the prevention of coronary heart disease. Gilliland, S.E., et al . , Applied and Environmental Microbiology, 49(2): 377-381, 1985, have found that some strains of Lactobacillus acidophilus, but not other, act directly on cholesterol in the gastrointestinal tract and may thus be beneficial in reducing serum cholesterol levels, and by this to lower the incidence of coronary heart disease. It is also reported that certain of said strains have the ability to deconjugate bile salts. In this study pigs were used as an animal model .
There is today no substance known that lowers the fibrinogen levels in patients at risk, safely and selectively.
Description of the invention
It has now surprisingly been found that orally administered live Lactobacillus bacteria bring about a decrease in the serum fibrinogen level. The invention consequently refers to the use of a strain of Lactobacillus for the manufacture of a medicament for reduction of the fibrinogen level in blood in mammals including man.
Optionally the administered strain of Lactobacillus also brings about a decrease in the serum cholesterol level . The invention therefore also refers to the use of a strain of
Lactobacillus for the manufacture of a medicament for reduction of the fibrinogen level as well as the cholesterol level in blood.
The invention also refers to the use of a strain of Lactobacillus in combination with an antihyperlipoprotein- emically active substance for the manufacture of a medicament for reduction of the fibrinogen level, as well as the cholesterol level, in blood. By this it will be possible to use a lower dose of the lipoprotein reducing drug, the administration of which is often associated with severe side effects .
In another aspect the invention refers to the use of a strain of Lactobacillus for the manufacture of a medicament for the prophylaxis and/or treatment of circulatory diseases, such as atherosclerosis, cardiovascular diseases, coronary heart disease, myocardial infarction, ischemic heart disease, stroke. A preferred strain oϊ Lactobacillus should be able to survive the passage through the stomach to the gastrointestinal tract and be able to colonize in the intestines. Two factors seem to be crucial for the exertion of ecological effects of Lactobacilli . The first is the capacity to colonize the intestine, that is to survive in high numbers for a period of time after the last administration of live bacteria. The second is the capacity to bind directly to intestinal epithelial cells. This may be one of the factors that promotes colonization, but is not a prerequisite for colonization. The ability to adhere to the epithelium does not guarantee that the strain is able to colonize. Examples of useful species of Lactobacillus are L. plantarum and L. rhamnosus . Different strains of of said lactobacilli are described in the International patent application WO 93/01823 refering to a process for isolation of strains of Lactobacillus having the ability to become established on the human intestinal mucosa in vivo- and also to remain thereon after oral administration for at least 10 days. Said application especially refers to two new Lactobacillus strains, which have been deposited according to the Budapest Agreement at the DSM - Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH -, Braunschweig, Germany on July 2, 1991, that is L. plantarum 299, number DSM 6595, and L. casei ssp. rhamnosus 271, number DSM 6594, as well as variants thereof. A preferred strain is Lactobacillus plantarum 299v, which has been deposited at the DSM on March 16, 1995 under number DSM 9843. This strain as well as other strains of L. plantarum are described in the International patent applica-tion WO 96/29083.
The Lactobacillus strain can be administered in any food or pharmaceutical composition which can preserve the viability of the strain in the large intestine. The composi- tion according to the invention can be administered in any suitable way, preferably orally or rectally, for example in the form of enema. It can also be administered enterally through a catheter inserted in the intestines via the stomach or directly in the intestines. A carrier for the strain of Lactobacillus in the pharmaceutical composition is for example a physiologically acceptable substrate fermented by the bacterium in question, especially based on starch or milk. A suitable substrate could contain liquid or solid fibres which are not resorbed in the gastro-intestinal tract. As an example of suitable, starch- containing substrates can be mentioned cereals, such as oats and wheat, corn, root vegetables such as potatoes and certain fruits such as green bananas . A preferred substrate for the pharmaceutical .composition according to the invention, which also gives the composition an excellent nutritional value, is a nutrient solution based on oatmeal, for instance as described in WO 89/08405. The fermented product can also be mixed with a foodstuff, preferably based on fruit or berries, such as rose- hip, blueberries, strawberries, but also with inert solid or liquid substances, such as saline or water.
The treatment should take place once or several times daily for a continuous period. In order to give a detectable result the strain of Lactobacillus should be administered in a daily dose of not less than about 1010 bacteria.
Biological test
The purpose of this study was to investigate the effect of a food product (ProViva®) containing Lactobacillus plantarum 299 v on serum lipid, especially LDL cholesterol, and fibrinogen levels in subjects with moderately elevated cholesterol concentrations. Material and methods
The ProViva® food product was a rose-hip drink containing oats (0.75 g of oat flour, that is 0.07 g of oat fibre/100 ml) . The product contains approximately 5 x 107 cfu/ml of Lactobacillus plantarum 299 v and about 0.035 g of DL-lactic acid/100 ml. In the manufacturing of this product the fermented oats and the rose-hip drink were made separately and then mixed together in the ratio 5 % (vol/vol) of fermented oats (containing 18.5 % (vol/vol) of oat flour) and 95 % (vol/vol) of rose-hip drink. Plain rose-hip drink, consisting of rose-hip powder, sucrose, thickening agent, citric acid, ascorbic acid and water, was used as placebo. The two products were both manufactured by Skanemejerier (Lunnarp, Sweden) .
The study was performed in 30 males aged 42.6 ± 2.8 years, previously screened for gastointestinal symptoms, medication, tobacco smoking, dietary habits and alcohol consumption. Individuals with cardiovascular disease, diabetes mellitus and arterial hypertension were excluded from the study. Body mass, height, arterial blood pressure and pulse rate were recorded and blood was collected for biochemical tests. A double-blind study with placebo was designed and the participants were randomly divided into two equal groups, to be given ProViva® or placebo, respectively. Characteristics of the subjects of the study are given in Table 1 below.
Each subject consumed 200 ml ProViva® or placebo on each morning for six weeks and maintained the same lifestyle as before. At the end of said period the participants were examined and blood was again collected.
Cholesterol and triglyceride levels in serum were determined using enzyme kits (CHOD-PAP, GPO-PAP) . HDL- cholesterol was measured after precipitation of lipoproteins containing apoB with phosphotungstic acid in the presence of
Mg2+ . LDL-cholesterol was determined after precipitation of LDL with polyvinyl sulfate. Laboratory procedures were based on test kits from Boehringer-Mannheim. Glucose was measured using glucose oxidase and test kits from Analco (PAP) and plasma fibrinogen determinations followed the method of Clauss based on thrombin time (test kits from bioMerieux) .
Table 1. Characteristics of the subjects in the two groups
Parameter ProViva® Placebo Number 15 15
Age (years) 43.0 ± 2.0 42.3 ± 3.0
BMI (kg/m2) 26.6 ± 3.7 25.9 ± 2.6
Systolic pressure (mm Hg) 133 ± 12 125 ± 15
Diastolic pressure (mm Hg) 88 + 7 83 + 9
Table 2. Biochemical parameters in the subjects after consumption of ProViva® or placebo
Parameter ProViva® Placebo mg/dl Before After 6 weeks Before After 6 weeks
Triglycerides 122 ± 61 121 ± 52 127 ± 42 112 ± 32
Cholesterol 233 + 36 216 + 33* 216 ± 31 208 ± 40
LDL-cholesterol 156 ± 36 141 ± 34* 140 ± 32 134 + 41
HDL-cholesterol 47 + 10 46 ± 10 48 ± 10 46 ± 8 Glucose 110 + 11 112 ± 11 104 + 10 109 ± 16
Fibrinogen 319 ± 82 276 ± 58** 320 ± 85 307 ± 60
* p < 0.01 ** p < 0.001
Results
There were no significant differences between the groups as to age, body mass index (BMI) , systolic or diastolic blood pressure (Table 1) . Results of the biochemical test are presented in Table 2. The initial concentrations of total cholesterol, LDL-cholesterol and fibrinogen were moderately elevated in both groups, but triglyceride and HDL-cholesterol values remained within normal limits. At this point no statistically significant differences between the groups were revealed.
The results are expressed in mg/dl . Mean values and standard deviations were calculated for the biochemical parameters and subjected to the unpaired Student's t-test between groups or the paired test within each group. The level of significance was taken as p < 0.05. After six weeks of the experiment the level of fibrinogen in the ProViva® group fell from 319 ± 82 to 276 + 58 mg/dl (p < 0.001), representing a reduction of 13.5% vs. the initial value. Similarly, the levels of total cholesterol and LDL-cholesterol were reduced by 7.3% (233 ± 33 to 216 ± 31) and 9.6% (156 + 36 to 141 + 34), respectively.- Triglyceride, glucose and HDL-cholesterol levels remained unchanged in this group.
In the placebo group no statistically significant differences between the initial and final values were observed. The present study confirms earlier observations that food products containing certain strains of Lactobacillus reduce blood cholesterol levels. However, for the first time it was found that a strain of Lactobacillus is effective in reducing the fibrinogen level. In conclusion, diet supplemenation with Lactobacillus could be beneficial to patients with moderately elevated cholesterol concentrations, reducing the risk of cardio-vascular disease.
It has already been confirmed that fibrinogen is an independent risk factor of ischemic heart disease and its level in blood is regulated by genetic and environmental factors. The finding that ProViva decreases both the level of fibrinogen and cholesterol may make it a promising food product in the early prevention of ischemic heart disease.

Claims

1. Use of a strain of Lactobacillus for the manufacture of a medicament for reduction of the fibrinogen level in blood in mammals including man.
2. Use of a strain of Lactobacillus in combination with an antihyperlipoproteinemically active substance for the manufacture of a medicament for reduction of the fibrinogen level, as well as the cholesterol level, in blood.
3. Use according to claim 1 or 2 , wherein the strain of Lactobacillus also reduces the cholesterol level in blood.
4. Use according to any of claims 1-3, for the manufacture of a medicament for the prophylaxis and/or treatment of circulatory diseases, such as atherosclerosis, cardiovascular diseases, coronary heart disease, myocardial infarction, ischemic heart disease, stroke.
5. Use according to any of claims 1-4, wherein the strain of Lactobacillus belongs to the species Lactobacillus plantarum or Lactobacillus rhamnosus.
6. Use according to any of claims 1-5 of Lactobacillus plantarum 299v, deposition number DSM 9843.
PCT/SE1998/001423 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood WO1999007827A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IL13411398A IL134113A0 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
CA2297023A CA2297023C (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
AU83726/98A AU729413B2 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
PL98338578A PL194697B1 (en) 1997-08-05 1998-07-30 Application of lactobacillus bacteria in lowering fibrinogen level in blood
NZ502610A NZ502610A (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
KR10-2000-7001211A KR100517755B1 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
US09/485,190 US6214336B1 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
EP98934131A EP0990024B1 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood
JP2000506312A JP4651814B2 (en) 1997-08-05 1998-07-30 Use of Lactobacillus to reduce blood fibrinogen levels
DE69834560T DE69834560T2 (en) 1997-08-05 1998-07-30 USE OF LACTOBACILLUS TO REDUCE FIBRINOGENIC CONTENT IN THE BLOOD
BR9811825-0A BR9811825A (en) 1997-08-05 1998-07-30 Use of lactobacillus to reduce the level of fibrinogen in the blood
NO20000268A NO324881B1 (en) 1997-08-05 2000-01-19 Use of a strain of Lactobacillus for the manufacture of a drug for the prophylaxis and / or treatment of circulatory diseases.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702860-9 1997-08-05
SE9702860A SE510753C2 (en) 1997-08-05 1997-08-05 Use of a strain of Lactobacillus for the manufacture of a drug for reducing fibrinogen content in blood

Publications (1)

Publication Number Publication Date
WO1999007827A1 true WO1999007827A1 (en) 1999-02-18

Family

ID=20407874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1998/001423 WO1999007827A1 (en) 1997-08-05 1998-07-30 Use of lactobacillus for reduction of the fibrinogen level in blood

Country Status (19)

Country Link
US (1) US6214336B1 (en)
EP (1) EP0990024B1 (en)
JP (1) JP4651814B2 (en)
KR (1) KR100517755B1 (en)
CN (1) CN1142995C (en)
AR (1) AR016798A1 (en)
AT (1) ATE326524T1 (en)
AU (1) AU729413B2 (en)
BR (1) BR9811825A (en)
CA (1) CA2297023C (en)
DE (1) DE69834560T2 (en)
ES (1) ES2259457T3 (en)
IL (1) IL134113A0 (en)
NO (1) NO324881B1 (en)
NZ (1) NZ502610A (en)
PL (1) PL194697B1 (en)
SE (1) SE510753C2 (en)
WO (1) WO1999007827A1 (en)
ZA (1) ZA986769B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1015933C2 (en) * 1999-03-04 2002-02-18 Bhph Company Ltd Lactic acid bacteria formulation for improving bowel movement, e.g. for treating diarrhea, comprising live microbes of Lactobacillus clearans and Enterococcus faecalis
WO2002034273A1 (en) * 2000-10-25 2002-05-02 Atheromastat Pty Ltd. Compositions and methods for diagnosis and treatment of cardiovascular disorders
WO2002038165A1 (en) * 2000-11-10 2002-05-16 Probi Ab Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome
US7001756B1 (en) * 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
CN102031229B (en) * 2009-09-24 2012-05-30 家医国际生化股份有限公司 Lactobacillus plantarum with gastrointestinal adsorption capacity and cholesterol removing capacity
EP2808024A1 (en) * 2009-06-19 2014-12-03 Dupont Nutrition Biosciences ApS Bifidobacteria for Treating myocardial infarction
WO2018234255A1 (en) * 2017-06-19 2018-12-27 Probi Ab Therapeutic uses of lactobacillus plantarum
EP3065571B1 (en) 2013-11-05 2019-10-16 Optibiotix Limited Composition
RU2772025C2 (en) * 2017-06-19 2022-05-16 Проби Аб THERAPEUTIC USE OF Lactobacillus plantarum

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1188140C (en) * 1998-10-01 2005-02-09 普罗比公司 Reduction of oxidative stress factors
SE523771C2 (en) * 1999-05-21 2004-05-18 Probi Ab Sports drinks containing micronutrients in combination with live lactobacilli
GB0124580D0 (en) * 2001-10-12 2001-12-05 Univ Reading New composition
KR20030033950A (en) * 2001-10-20 2003-05-01 주식회사 알엔에이 Arteriosclerosis inhibitory agent comprising cytoplasmic fraction or debris derived from lactic acid bacteria as an active ingredient
FR2831395B1 (en) * 2001-10-25 2004-06-11 Triballat Laiteries PROCESS FOR THE PRODUCTION OF FERMENTED SOYBEAN PRODUCTS, FERMENTED PRODUCTS OBTAINED THEREBY AND CORRESPONDING FERMENTS
TWI241912B (en) * 2002-10-30 2005-10-21 Food Industry Res & Dev Inst Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol
SE527555C2 (en) * 2003-04-04 2006-04-11 Probi Ab Composition for treating cardiovascular disease, diabetes, cancer, Alzheimer's disease, has tannase-producing strains of Lactobacillus plantarum or Lactobacillus species that adhere to human intestinal mucosa in combination with tannin
CN1207382C (en) * 2003-04-11 2005-06-22 上海光明乳业股份有限公司 Lactob.plantarum ST-III strain and application in regulating blood fat
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
GB0424552D0 (en) * 2004-11-05 2004-12-08 Cambridge Theranostics Ltd Methods and means
CA2607949C (en) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Feline probiotic bifidobacteria
DK1880001T3 (en) 2005-05-31 2011-09-12 Iams Company Feline probiotic lactobacilli
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
KR100909586B1 (en) * 2007-06-01 2009-07-27 신현길 Lactic acid bacteria and mixed strains thereof effective in lowering blood cholesterol levels
SE532899C2 (en) * 2007-06-08 2010-05-04 Probi Ab Process by fermentation with Lactobacillus plantarum to provide an insulin response reducing product and its use pharmaceutically or in food
JP5469873B2 (en) * 2008-03-11 2014-04-16 株式会社日立製作所 Rotating electric machine
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
JP5140791B2 (en) * 2008-11-27 2013-02-13 森下仁丹株式会社 Lactic acid bacteria-containing blood homocysteine reducing agent
US9474773B2 (en) 2009-02-18 2016-10-25 University Of Florida Research Foundation, Inc. Lactobacillus supplement for alleviating type 1 diabetes
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
EA024911B1 (en) * 2010-01-08 2016-11-30 Компани Жервэ Данон Lactobacilli with anti-oxidant action
GB201319540D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
CN110786435B (en) * 2019-11-19 2022-08-23 四川农业大学 Lactobacillus plantarum for producing high-activity plasminogen activator and fruit and vegetable juice beverage fermented by lactobacillus plantarum

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671468A1 (en) * 1994-03-11 1995-09-13 The Calpis Food Industry Co., Ltd. Lactic acid bacteria of the genus lactobacillus
JPH08208512A (en) * 1995-02-03 1996-08-13 Nippon Chem Res Kk Medicine for inhibiting thrombogenesis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0647551B2 (en) * 1986-12-01 1994-06-22 株式会社ヤクルト本社 Antihypertensive agent
JP2676250B2 (en) * 1989-03-20 1997-11-12 株式会社ヤクルト本社 Antihypertensive agent and method for producing the same
JP2855290B2 (en) * 1990-11-30 1999-02-10 株式会社ヤクルト本社 Lipid metabolism improver
JPH04264034A (en) * 1991-02-18 1992-09-18 Snow Brand Milk Prod Co Ltd Agent for suppressing lipid peroxide in living body
JPH0525055A (en) * 1991-07-22 1993-02-02 Yakult Honsha Co Ltd Hypotensive agent
SE469875C (en) * 1991-07-25 1997-02-05 Probi Ab Strain of intestinal colonizing Lactobacillus and composition for prophylaxis or treatment of gastrointestinal infections
JPH06116155A (en) * 1992-10-08 1994-04-26 Yakult Honsha Co Ltd Serum cholesterol lowering agent
JP2801479B2 (en) * 1992-10-09 1998-09-21 株式会社トクヤマ Prosthetic material manufacturing method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671468A1 (en) * 1994-03-11 1995-09-13 The Calpis Food Industry Co., Ltd. Lactic acid bacteria of the genus lactobacillus
JPH08208512A (en) * 1995-02-03 1996-08-13 Nippon Chem Res Kk Medicine for inhibiting thrombogenesis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ATHEROSCLEROSIS, vol. 137, no. 2, April 1998 (1998-04-01), IRELAND, pages 437 - 438 *
CHEMICAL ABSTRACTS, Volume 125, No. 15, 7 Sept. 1996, (Columbus, Ohio, USA), Abstract No. 194329, PARK SO-YOUNG et al., "Effect of Various Lactic Acid Bacteria on the Serum Cholesterol Levels in Rats and Resistance to Acid, Bile and Antibiotics"; & SANOP MISAENGMUL HAKHOECHI, 1996, 24(3), 304-310. *
DATABASE BIOSIS [online] OAKEY H.J. ET AL.: "Enzyme Production of Lactobacilli and the Potential Link with Infective Endocarditis", XP002952865, accession no. DIALOG Database accession no. 98141251 *
DATABASE MEDLINE [online] BUKOWSKA H ET AL.: "Decrease in Fibrinogen and LDL-Cholesterol Levels Upon Supplementation of Diet with Lactobacillus Plantarum in Subjects with Moderately Elevated Cholesterol Letter", XP002952866, accession no. DIALOG Database accession no. 98283630 *
DATABASE WPI Derwent World Patents Index; AN 1996-421913, XP002952864, "Anti-Thrombotic Agent, Inhibiting Recurrent Thrombosis - Contains the Fibrinolytic Enzyme,Nattokinase Produced by Bacillus Natto" *
JOURNAL OF APPLIED BACTERIOLOGY, vol. 78, no. 2, 1995, pages 142 - 148 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1015933C2 (en) * 1999-03-04 2002-02-18 Bhph Company Ltd Lactic acid bacteria formulation for improving bowel movement, e.g. for treating diarrhea, comprising live microbes of Lactobacillus clearans and Enterococcus faecalis
WO2002034273A1 (en) * 2000-10-25 2002-05-02 Atheromastat Pty Ltd. Compositions and methods for diagnosis and treatment of cardiovascular disorders
WO2002038165A1 (en) * 2000-11-10 2002-05-16 Probi Ab Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome
AU2002214486B2 (en) * 2000-11-10 2007-04-26 Probi Ab Use of a strain of Lactobacillus reducing the risk factors involved in the metabolic syndrome
US7001756B1 (en) * 2004-02-19 2006-02-21 Genmont Biotech Inc. Microorganism strain of GM-020 of Lactobacillus rhamnosus and its use for treating obesity
EP2808024A1 (en) * 2009-06-19 2014-12-03 Dupont Nutrition Biosciences ApS Bifidobacteria for Treating myocardial infarction
CN102031229B (en) * 2009-09-24 2012-05-30 家医国际生化股份有限公司 Lactobacillus plantarum with gastrointestinal adsorption capacity and cholesterol removing capacity
EP3065571B1 (en) 2013-11-05 2019-10-16 Optibiotix Limited Composition
WO2018234255A1 (en) * 2017-06-19 2018-12-27 Probi Ab Therapeutic uses of lactobacillus plantarum
CN111565734A (en) * 2017-06-19 2020-08-21 普罗比公司 Therapeutic use of lactobacillus plantarum
RU2772025C2 (en) * 2017-06-19 2022-05-16 Проби Аб THERAPEUTIC USE OF Lactobacillus plantarum
US11723936B2 (en) 2017-06-19 2023-08-15 Probi Ab Therapeutic uses of Lactobacillus plantarum

Also Published As

Publication number Publication date
SE9702860D0 (en) 1997-08-05
JP2001512747A (en) 2001-08-28
AR016798A1 (en) 2001-08-01
CA2297023C (en) 2010-03-30
CN1265141A (en) 2000-08-30
DE69834560D1 (en) 2006-06-22
SE510753C2 (en) 1999-06-21
EP0990024A1 (en) 2000-04-05
ATE326524T1 (en) 2006-06-15
KR100517755B1 (en) 2005-09-30
AU8372698A (en) 1999-03-01
CN1142995C (en) 2004-03-24
NO20000268D0 (en) 2000-01-19
PL194697B1 (en) 2007-06-29
NO324881B1 (en) 2007-12-27
DE69834560T2 (en) 2006-11-02
KR20010022617A (en) 2001-03-26
ES2259457T3 (en) 2006-10-01
BR9811825A (en) 2000-08-15
JP4651814B2 (en) 2011-03-16
SE9702860L (en) 1999-02-06
NO20000268L (en) 2000-01-19
AU729413B2 (en) 2001-02-01
US6214336B1 (en) 2001-04-10
IL134113A0 (en) 2001-04-30
ZA986769B (en) 1999-02-02
CA2297023A1 (en) 1999-02-18
EP0990024B1 (en) 2006-05-17
PL338578A1 (en) 2000-11-06
NZ502610A (en) 2000-12-22

Similar Documents

Publication Publication Date Title
AU729413B2 (en) Use of lactobacillus for reduction of the fibrinogen level in blood
CA2434035C (en) Use of a strain of lactobacillus reducing the risk factors involved in the metabolic syndrome
EP2277524B1 (en) Treatment of IBS using both probiotic bacteria and fermented cereal as treatment effectors
EP2163162B1 (en) Compositions comprising Lactobacillus plantarum strains in combination with tannin and new Lactobacillus plantarum strains
JP4737836B2 (en) Dietary or pharmaceutical composition for prevention or treatment of hyperoxaluria
US20080102061A1 (en) Use hydrolyzed medium containing microorganisms medicinally
AU2002214486A1 (en) Use of a strain of Lactobacillus reducing the risk factors involved in the metabolic syndrome
WO2002076240A1 (en) Health foods containing natto kinase and fermented milk porducts
RU2671221C2 (en) Compositions comprising mixture of bacteria comprising pedoiococcus and lactobacillus and methods for decreasing effects of alcohol
JP2002526413A (en) Reduction of oxidative stress factors
KR100404236B1 (en) Microorganisms for Corpulence or Diabetes Mellitus, or a pharmaceutical composition containing the same
JP2013047197A (en) Spirulina composition
CN111560335A (en) Bifidobacterium lactis for relieving asthma and application thereof
KR100523661B1 (en) Use of propionic bacteria for producing propionic acid and/or propionates in the colon
JP2690130B2 (en) Lipid peroxide reducer
CN117384788A (en) Saliva combined lactobacillus SM4 and application thereof in preparation of whitening and cholesterol lowering foods and medicines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134113

Country of ref document: IL

Ref document number: 98807635.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 83726/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2297023

Country of ref document: CA

Ref document number: 2297023

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998934131

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020007001211

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 502610

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09485190

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998934131

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007001211

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 83726/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020007001211

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998934131

Country of ref document: EP